Insight Molecular Diagnostics (IMDX) expects to respond before a January 2027 deadline to the U.S. Food and Drug Administration's request for more information about its GraftAssureDx kidney transplant test, executives said on the company's third-quarter earnings call.
President and CEO Josh Riggs s...